Free Trial
NASDAQ:CGON

CG Oncology (CGON) Stock Price, News & Analysis

CG Oncology logo
$39.82 -0.03 (-0.08%)
Closing price 10/3/2025 04:00 PM Eastern
Extended Trading
$39.64 -0.18 (-0.46%)
As of 10/3/2025 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About CG Oncology Stock (NASDAQ:CGON)

Advanced

Key Stats

Today's Range
$39.15
$40.27
50-Day Range
$23.94
$40.28
52-Week Range
$14.80
$40.65
Volume
560,483 shs
Average Volume
1.23 million shs
Market Capitalization
$3.04 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$56.55
Consensus Rating
Moderate Buy

Company Overview

CG Oncology Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
50th Percentile Overall Score

CGON MarketRank™: 

CG Oncology scored higher than 50% of companies evaluated by MarketBeat, and ranked 572nd out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    CG Oncology has received a consensus rating of Moderate Buy. The company's average rating score is 2.79, and is based on 10 buy ratings, 2 hold ratings, and 1 sell rating.

  • Upside Potential

    CG Oncology has a consensus price target of $56.55, representing about 42.0% upside from its current price of $39.82.

  • Amount of Analyst Coverage

    CG Oncology has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about CG Oncology's stock forecast and price target.
  • Earnings Growth

    Earnings for CG Oncology are expected to decrease in the coming year, from ($1.31) to ($1.77) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of CG Oncology is -22.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of CG Oncology is -22.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    CG Oncology has a P/B Ratio of 4.13. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about CG Oncology's valuation and earnings.
  • Percentage of Shares Shorted

    24.17% of the float of CG Oncology has been sold short.
  • Short Interest Ratio / Days to Cover

    CG Oncology has a short interest ratio ("days to cover") of 11.8, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in CG Oncology has recently increased by 7.62%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    CG Oncology does not currently pay a dividend.

  • Dividend Growth

    CG Oncology does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    24.17% of the float of CG Oncology has been sold short.
  • Short Interest Ratio / Days to Cover

    CG Oncology has a short interest ratio ("days to cover") of 11.8, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in CG Oncology has recently increased by 7.62%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    CG Oncology has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 11 news articles for CG Oncology this week, compared to 6 articles on an average week.
  • Search Interest

    4 people have searched for CGON on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • MarketBeat Follows

    1 people have added CG Oncology to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, CG Oncology insiders have bought 841.95% more of their company's stock than they have sold. Specifically, they have bought $49,999,983.00 in company stock and sold $5,308,111.00 in company stock.

  • Percentage Held by Insiders

    Only 7.40% of the stock of CG Oncology is held by insiders.

  • Percentage Held by Institutions

    Only 26.56% of the stock of CG Oncology is held by institutions.

  • Read more about CG Oncology's insider trading history.
Receive CGON Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CG Oncology and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CGON Stock News Headlines

CG Oncology (NASDAQ:CGON) Director Sells $200,450.00 in Stock
$100 Trillion “AI Metal” Found in American Ghost Town
Jeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could be the biggest technology story of this decade. In short, he believes what he's holding in his hand is the key to the $100 trillion AI boom… And only one company here in the U.S. can mine this obscure metal.tc pixel
CG Oncology, Inc. (NASDAQ:CGON) Receives $56.55 Consensus PT from Analysts
See More Headlines

CGON Stock Analysis - Frequently Asked Questions

CG Oncology's stock was trading at $28.68 at the beginning of the year. Since then, CGON stock has increased by 38.8% and is now trading at $39.82.

CG Oncology, Inc. (NASDAQ:CGON) issued its quarterly earnings results on Friday, August, 8th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.49) by $0.05. CG Oncology had a negative trailing twelve-month return on equity of 19.37% and a negative net margin of 15,945.17%.

CG Oncology (CGON) raised $380 million in an initial public offering on Thursday, January 25th 2024. The company issued 20,000,000 shares at $19.00 per share.

Shares of CGON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that CG Oncology investors own include Invesco QQQ (QQQ), SPDR Dow Jones Industrial Average ETF Trust (DIA), SPDR S&P 500 ETF Trust (SPY), Meta Platforms (META), Advanced Micro Devices (AMD), NVIDIA (NVDA) and Tesla (TSLA).

Company Calendar

Last Earnings
8/08/2025
Today
10/05/2025
Next Earnings (Estimated)
11/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CGON
Previous Symbol
NASDAQ:CGON
CIK
1991792
Fax
N/A
Employees
61
Year Founded
N/A

Price Target and Rating

High Price Target
$79.00
Low Price Target
$23.00
Potential Upside/Downside
+42.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.79
Research Coverage
14 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.77)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$88.04 million
Net Margins
-15,945.17%
Pretax Margin
-23,245.19%
Return on Equity
-19.37%
Return on Assets
-18.72%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
22.15
Quick Ratio
22.15

Sales & Book Value

Annual Sales
$1.14 million
Price / Sales
2,663.40
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$9.63 per share
Price / Book
4.13

Miscellaneous

Outstanding Shares
76,250,000
Free Float
70,606,000
Market Cap
$3.04 billion
Optionable
Optionable
Beta
1.31
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

This page (NASDAQ:CGON) was last updated on 10/5/2025 by MarketBeat.com Staff
From Our Partners